Dionisi S, Dotta F, Diaz-Horta O, Carabba B, Viglietta V, Di Mario U
II Clinica Medica-Endocrinologia, Università degli Studi La Sapienza, Rome, Italy.
Ann Ist Super Sanita. 1997;33(3):433-5.
Type 1 diabetes mellitus is a disease caused by the autoimmune destruction of insulin-producing pancreatic beta-cells that takes place in genetically prodisposed individuals. Autoantibodies and autoreactive T lymphocytes reacting with islet target molecules or protein of glycolipid nature have been shown in the circulation of individuals and of animal models of type 1 diabetes (NOD mouse and BB rat) before and at the onset of the disease. As far as autoantigens of glycolipid nature is concerned, gangliosides such as GT3, GD3 and especially GM-1, have been shown to be target of autoantibodies associated to autoimmune diabetes. Of particular interest is the islet-specific monosialo-ganglioside GM2-1, which is target of an autoimmune response highly associated to future progression to diabetes development in first degree relatives of type 1 diabetic individuals. This molecule is recognized by IgG autoantibodies which have been detected before the appearance if clinical diabetes both in man and in the NOD mouse, representing a novel marker of beta-cell autoimmunity.
1型糖尿病是一种由胰岛素生成胰腺β细胞的自身免疫性破坏所引起的疾病,这种破坏发生在具有遗传易感性的个体中。在1型糖尿病患者以及动物模型(非肥胖糖尿病小鼠和BB大鼠)发病前和发病时,其血液循环中已发现与胰岛靶分子或糖脂性质蛋白质发生反应的自身抗体和自身反应性T淋巴细胞。就糖脂性质的自身抗原而言,神经节苷脂如GT3、GD3,尤其是GM-1,已被证明是与自身免疫性糖尿病相关的自身抗体的靶标。特别值得关注的是胰岛特异性单唾液酸神经节苷脂GM2-1,它是一种自身免疫反应的靶标,与1型糖尿病患者一级亲属未来发展为糖尿病的高度相关性。该分子可被IgG自身抗体识别,在人类和非肥胖糖尿病小鼠出现临床糖尿病之前就能检测到这些抗体,这代表了β细胞自身免疫的一种新标志物。